Immunovant, Inc. (IMVT)


-0.21 (-4.04%)
Symbol IMVT
Price $4.99
Beta 1.010
Volume Avg. 0.31M
Market Cap 581.719M
Shares () -
52 Week Range 3.145-9.535
1y Target Est -
DCF Unlevered IMVT DCF ->
DCF Levered IMVT LDCF ->
ROE -34.22% Strong Sell
ROA -36.33% Strong Sell
Operating Margin -
Debt / Equity 5.08% Neutral
P/E -
P/B 1.33 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest IMVT news

Dr. Peter Salzmann M.B.A., M.D.
NASDAQ Global Select

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.